vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ACME UNITED CORP is the larger business by last-quarter revenue ($52.3M vs $28.1M, roughly 1.9× ARS Pharmaceuticals, Inc.). ACME UNITED CORP runs the higher net margin — 1.9% vs -147.1%, a 149.0% gap on every dollar of revenue. On growth, ACME UNITED CORP posted the faster year-over-year revenue change (13.8% vs -67.6%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
ACU vs SPRY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $28.1M |
| Net Profit | $985.0K | $-41.3M |
| Gross Margin | 39.7% | — |
| Operating Margin | 3.3% | -147.6% |
| Net Margin | 1.9% | -147.1% |
| Revenue YoY | 13.8% | -67.6% |
| Net Profit YoY | -40.4% | -182.8% |
| EPS (diluted) | $0.24 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | $28.1M | ||
| Q3 25 | $49.1M | $32.5M | ||
| Q2 25 | $54.0M | $15.7M | ||
| Q1 25 | $46.0M | $8.0M | ||
| Q4 24 | $45.9M | $86.6M | ||
| Q3 24 | $48.2M | $2.1M | ||
| Q2 24 | $55.4M | $500.0K |
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | $-41.3M | ||
| Q3 25 | $1.9M | $-51.2M | ||
| Q2 25 | $4.8M | $-44.9M | ||
| Q1 25 | $1.7M | $-33.9M | ||
| Q4 24 | $1.7M | $49.9M | ||
| Q3 24 | $2.2M | $-19.1M | ||
| Q2 24 | $4.5M | $-12.5M |
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | — | ||
| Q3 25 | 39.1% | — | ||
| Q2 25 | 41.0% | — | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 40.8% | — |
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | -147.6% | ||
| Q3 25 | 6.1% | -163.7% | ||
| Q2 25 | 11.8% | -302.9% | ||
| Q1 25 | 5.3% | -466.3% | ||
| Q4 24 | 5.0% | 54.5% | ||
| Q3 24 | 6.1% | -1051.6% | ||
| Q2 24 | 11.5% | -3068.0% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | -147.1% | ||
| Q3 25 | 3.9% | -157.4% | ||
| Q2 25 | 8.8% | -285.6% | ||
| Q1 25 | 3.6% | -425.7% | ||
| Q4 24 | 3.7% | 57.7% | ||
| Q3 24 | 4.6% | -925.0% | ||
| Q2 24 | 8.0% | -2503.2% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $-0.41 | ||
| Q3 25 | $0.46 | $-0.52 | ||
| Q2 25 | $1.16 | $-0.46 | ||
| Q1 25 | $0.41 | $-0.35 | ||
| Q4 24 | $0.43 | $0.52 | ||
| Q3 24 | $0.54 | $-0.20 | ||
| Q2 24 | $1.09 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $245.0M |
| Total DebtLower is stronger | $33.0M | $96.4M |
| Stockholders' EquityBook value | $116.7M | $114.3M |
| Total Assets | $195.2M | $327.7M |
| Debt / EquityLower = less leverage | 0.28× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | $245.0M | ||
| Q3 25 | $5.1M | $288.2M | ||
| Q2 25 | $3.6M | $240.1M | ||
| Q1 25 | $3.4M | $275.7M | ||
| Q4 24 | $6.4M | $314.0M | ||
| Q3 24 | $5.7M | $204.6M | ||
| Q2 24 | $3.8M | $218.7M |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $114.3M | ||
| Q3 25 | $115.8M | $147.7M | ||
| Q2 25 | $113.7M | $192.3M | ||
| Q1 25 | $108.3M | $229.0M | ||
| Q4 24 | $107.0M | $256.8M | ||
| Q3 24 | $106.3M | $201.0M | ||
| Q2 24 | $104.0M | $215.2M |
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | $327.7M | ||
| Q3 25 | $173.0M | $372.8M | ||
| Q2 25 | $170.9M | $313.5M | ||
| Q1 25 | $163.0M | $327.3M | ||
| Q4 24 | $162.2M | $351.2M | ||
| Q3 24 | $165.5M | $217.6M | ||
| Q2 24 | $173.5M | $222.0M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $-43.5M | ||
| Q3 25 | $7.1M | $-47.0M | ||
| Q2 25 | $6.3M | $-39.6M | ||
| Q1 25 | $-3.3M | $-40.7M | ||
| Q4 24 | $6.4M | $42.0M | ||
| Q3 24 | $8.9M | $-14.5M | ||
| Q2 24 | $6.9M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | — | ||
| Q3 25 | $301.0K | $-47.2M | ||
| Q2 25 | $4.7M | $-39.6M | ||
| Q1 25 | $-4.7M | $-40.8M | ||
| Q4 24 | $4.7M | $41.7M | ||
| Q3 24 | $7.5M | $-14.6M | ||
| Q2 24 | $4.4M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 0.6% | -145.4% | ||
| Q2 25 | 8.7% | -252.2% | ||
| Q1 25 | -10.2% | -512.1% | ||
| Q4 24 | 10.2% | 48.2% | ||
| Q3 24 | 15.6% | -706.3% | ||
| Q2 24 | 8.0% | -1463.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 0.0% | ||
| Q3 25 | 13.8% | 0.6% | ||
| Q2 25 | 3.0% | 0.3% | ||
| Q1 25 | 2.9% | 1.1% | ||
| Q4 24 | 3.7% | 0.3% | ||
| Q3 24 | 2.8% | 6.8% | ||
| Q2 24 | 4.5% | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | — | ||
| Q3 25 | 3.72× | — | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | -2.02× | — | ||
| Q4 24 | 3.73× | 0.84× | ||
| Q3 24 | 3.99× | — | ||
| Q2 24 | 1.55× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACU
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
